Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Epidiferphane** is an orally administered proprietary polymolecular botanical nutritional supplement developed as a supportive-care intervention alongside taxane chemotherapy. It contains curcumin, epigallocatechin gallate from green tea, and sulforaphane from broccoli sprouts. The formulation is being evaluated for mitigation of taxane-associated toxicities, particularly peripheral neuropathy, anemia, neutropenia, and inflammatory symptoms, while potentially preserving chemotherapy dose intensity and tumor response. Its proposed activity is anti-inflammatory and cytoprotective, including modulation of inflammatory cytokines and the NLRP3 inflammasome. ([cancer.gov](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/epidiferphane))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Epidiferphane.